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Human oncogenic viruses include Epstein–Barr virus, hepatitis B virus, hepatitis C virus,
human papilloma virus, humanT-cell lymphotropic virus, Kaposi’s associated sarcoma virus,
and Merkel cell polyomavirus. It would be expected that during virus–host interaction, the
immune system would recognize these pathogens and eliminate them. However, through
evolution, these viruses have developed a number of strategies to avoid such an outcome
and successfully establish chronic infections.The persistent nature of the infection caused
by these viruses is associated with their oncogenic potential. In this article, we will review
the latest information on the interaction between oncogenic viruses and the innate immune
system of the host. In particular, we will summarize the available knowledge on the recog-
nition by host pattern-recognition receptors of pathogen-associated molecular patterns
present in the incoming viral particle or generated during the virus’ life cycle. We will also
review the data on the recognition of cell-derived danger associated molecular patterns
generated during the virus infection that may impact the outcome of the host–pathogen
interaction and the development cancer.
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INTRODUCTION
Seven human viruses have been found so far to cause approxi-
mately 10–20% of human cancers worldwide (1). They include
the herpesviruses, Epstein–Barr virus (EBV) and Kaposi’s associ-
ated sarcoma virus (KSHV), the hepatitis B (HBV) and hepatitis
C (HCV) viruses, high-risk human papillomaviruses (HPV) (the
most clinically important ones being types 16 and 18, but most
probably a few others will be found to be relevant to cancer devel-
opment as well in the future), the human T-cell lymphotropic
virus-1 (HTLV-1), and the recently discovered Merkel cell poly-
omavirus (MCPyV) (1). The mechanisms by which these viruses
cause cancer are diverse. They have prolonged latency periods,
during which viral factors combine with other environmental
factors in the setting of the genetic background of each partic-
ular host (2). However, it could be proposed that these viruses
have no intention of generating disease in their hosts, as evi-
denced by the overall rate of disease/infected humans worldwide
for each virus (Table 1). Although exact numbers are not avail-
able for every region in the world, the number of humans that
suffer a disease associated with each oncogenic virus, as com-
pared to the number of people infected with each virus is evi-
dently low. It appears that during evolution these viruses have
found a balance of “live and let live” with their host. Until
very recently in history, humans were not living long enough to
considerably suffer from the diseases attributed to these viruses
(3). Today, however, human longevity is greatly extended, and
although the burden of diseases associated with oncogenic viruses
is still low in comparison with the number of infected people,
the goal of medicine is, of course, to eradicate diseases. Under-
standing the interactions of these viruses with the host will cer-
tainly help to achieve this goal. Of particular importance is their
interaction with the innate immune system, which functions to
recognize non-self like microorganisms, and also plays a criti-
cal role in recognition of modified self that indicates damage or
danger (4).
Germline-encoded pattern-recognition receptors (PRRs) rec-
ognize chemically distinct moieties in microorganisms or
“pathogen-associated molecular patterns” (PAMPs) (12). PRRs
can also recognize endogenous host molecules that in different
ways signal danger (“damage” or “danger”-associated molecular
patterns’ or “DAMPs”) (13, 14). It is noteworthy that the “D” in
DAMPs is used interchangeably for “danger” or “damage.” How-
ever, “danger” would seem to be more appropriate, as there could
be danger without damage, and it would be more in line with
the original “danger” theory proposed by Matzinger several years
ago (15).
There are two families of transmembrane PRRs, namely toll-
like receptors (TLRs) (16) and C-type lectin receptors (CLRs)
(17). They are positioned to scan the extracellular and endoso-
mal spaces. The families of cytoplasmic PRRs include the retinoic
acid-inducible gene (RIG)-I-like receptors (RLRs) (18) and the
nucleotide-binding, oligomerization domain (NOD)-like recep-
tors (NLRs) (19, 20), as well as a large number of DNA sensors
that converge in the adaptor for cytosolic DNA sensing stimula-
tor of interferon genes (STING). An excellent very comprehensive
review on nucleic acid sensing was recently published (21). The
double-stranded (ds)RNA-dependent protein kinase R (PKR) and
the 2′,5′-oligoadenylate synthetases (OAS) are considered part of
the cytoplasmic PRRs as well (22). Recently, a nuclear DNA sen-
sor was identified, IFI-16, a PYHIN protein that, together with
the cytoplasmic AIM-2 DNA sensor, was proposed to form a new
family of innate DNA sensors (“AIM2-like receptors” or “ALRs”)
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Table 1 | Oncoviruses induce cancer in only a fraction of infected humans.
Virus Family Infected worldwide (estimated) Percentage developing disease* Reference
HBV Hepadnaviridae 400 million HCC: 340,000/year (1% approximately) Busca and Kumar (5)
HCV Flaviviridae 210 million; 80% persistent infection HCC: 195,000/year (1% approximately) Eksioglu et al. (6)
EBV Herpesviridae 90% Human population (approximately 6.3 billion?) Most people do not develop disease Zauner and Nadal (7)
KSHV Herpesviridae Not ubiquitous, perhaps between 5 and 50% of the
population
Varies Areste and
Blackbourn (8)
HPV Papillomaviridae 50–80% Of sexually active adults; one or more HPV
types during lifetime
Invasive cervical cancer: 500,000
cases/year
Sunthamala et al. (9)
HTLV-1 Retroviridae 10–20 million 2–3% ATL; 0.25–4% HAM/TSP Oliere et al. (10)
MCPyV Polyomaviridae Reports vary, between 20 and 80% of population tested MCC: 1600 cases year in USA Bhatia et al. (11)
*Numbers are approximate, and may vary in different geographical regions.
HCC, hepatocellular carcinoma; MCC, Merkel cell carcinoma. See other abbreviations in text.
(23). Importantly, some of the members of the NLR and ALR fam-
ilies form a molecular complex termed “inflammasomes,” molec-
ular platforms that control the secretion of the pro-inflammatory
cytokines interleukin-1b and -18 (14). Some of the members of
the already mentioned families of receptors recognize DNA. How-
ever, there is a growing list of DNA sensors not belonging to these
families, recognizing both pathogen’s DNA as well as modified or
displaced self DNA (24). Finally, although it is not be in the scope
of this review, it is relevant to mention here that there is a par-
ticular set of immune proteins called “intrinsic antiviral factors.”
Unlike PRRs that function against viruses by triggering a cascade of
antiviral signaling events, intrinsic antiviral factors directly block
viruses at different points of their life cycle (25). Each of these fam-
ilies of proteins does work in concert in order to eradicate viruses.
However, viruses have evolved a myriad of mechanisms to evade
and subvert these host antiviral defenses in order to ensure their
evolutionary survival (26).
There is abundant information on the mechanisms by which
the seven oncogenic viruses block the molecular pathways of the
innate immune system at the level of intracellular adaptors, and
the reader is referred to the several extensive published reviews in
the specific sections below. However, much less is known on the
recognition of these viruses by the sensors that physically interact
with viral PAMPs. Here, we will focus on the latest findings on the
growing list of innate immune sensors that have been implicated
in sensing each known human oncogenic virus (Figure 1). We
believe that by combining this information in one single review,
parallelisms and differences between these very distinct viruses,
which trigger the same human disease, i.e., cancer, may be revealed.
HEPATITIS C VIRUS
Hepatitis C virus is a single-stranded RNA virus, with an enveloped
nucleocapsid of about 50 nm. It is transmitted via parenteral route,
and there are millions of people infected with HCV worldwide,
for which there is no available vaccine (27). During its evolu-
tion with the host, it has developed a number of mechanisms to
avoid being eliminated by the innate immune system, establishing
chronic infection of the liver. This chronic infection triggers injury
to the liver, which is believed to be the basis for the development of
liver cancer. HCV and its interaction with the adaptive and innate
immune systems is a very active field of research, and many recent
review articles have exhaustively discussed these topics (6, 27–32).
However, the sensing of the virus and the innate pathways acti-
vated during the first days of infection in humans remain largely
unknown (33). Understanding of these steps is critical, as they are
likely to set the stage for the ultimate outcome of the infection.
CELLULAR MEMBRANE AND ENDOSOME SENSING
TLR2 has been proposed to sense HCV proteins at the cell sur-
face (30). TLR3 has been shown to be relevant for the activation
of the transcription factors IRF-3 and NF-κB in response to
HCV–RNA (28). TLR7 was also shown to be relevant in HCV
sensing (34), and the proposed mechanism suggested the exis-
tence of a cell–cell RNA transfer process where HCV-infected cells
activated plasmacytoid dendritic cells (pDCs) in trans. This was
shown to be the case as well by Dreux et al., who reported the
transfer of HCV–RNA containing exosomes from infected cells to
pDCs (35).
INTRACELLULAR SENSING
Hepatitis C virus recognition in the cytosol is mediated by the
host RNA-dependent PKR, which identifies an internal ribosome
entry site (IRES) in HCV genome. In contrast, the virus’ 3′ poly-
U/UC sequence, short dsRNA regions, and 5′ triphosphate of the
uncapped HCV–RNA are recognized by RIG-I [reviewed in detail
by Horner (28); Horner and Gale (29)]. A detailed analysis of the
HCV–RNA that activates RIG-I was described by Schnell et al. (36),
who reported a 34-nt poly-uridine“core”of the 5′-ppp poly-U/UC
sequence as a critical structure for RIG-I activation. Recently, a
new mechanism by which HCV controls interferon (IFN) induc-
tion was described, where RIG-I is ubiquitinated through the
di-ubiquitin-like protein ISG15,one of the early interferon respon-
sive genes (ISGs) (37). Other investigators, however, propose a
different mechanism of RIG-I activation, where Riplet-mediated
K63-linked polyubiquitination releases RIG-I RD autorepression,
allowing the access of downstream signaling factors to the RIG-I
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 353 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Di Paolo Oncogenic viruses recognition by PRRs
FIGURE 1 | Molecular sensors that have been proposed to detect
oncolytic viruses (to the best of our knowledge, no sensor has
been yet definitively shown for MCPyV). It should be noted that
most of the interactions between the described oncolytic viruses and
the proposed sensor awaits verification in relevant in vivo models.
Question marks are intended to denote those sensors for which there
is particularly conflicting data; please see specific sections in text for
further details.
protein (38). These differences in the proposed models of RIG-I
activation may be due to the use of different cell types and exper-
imental conditions. More recent data also suggest that the STING
may be relevant for HCV recognition (39, 40). The mechanism
these investigators propose implicates direct interaction of HCV
NS4B with STING, blocking IFN beta production downstream
of both STING and RIG-I. Finally, although human biopsies pro-
vide limited opportunities for mechanistic studies, they are critical
since they allow a snapshot view of the tissue that is infected in the
actual host. Consistent with this concept, Mozer-Lisewska et al.
reported that in liver from patients with chronic hepatitis C infec-
tion, the expression of TLR1, 2, 4, NALP, and RIG-I helicase was
markedly increased, suggesting that these PRRs may be impor-
tant for the pathogenesis of chronic viral hepatitis by HCV in
humans (41).
HEPATITIS B VIRUS
Hepatitis B virus genome consists of partial dsDNA, its nucleo-
capside is enveloped, and is transmitted via the parenteral route;
although there is a vaccine available, millions of people are infected
(27). The major challenge for mechanistic analysis of HBV inter-
action with the innate immune system is the lack of a suitable
animal model. Woodchuck infected with the woodchuck hepati-
tis virus (WHV) (42) is an accepted study model, but available
immunological tools are limited. Researchers use transfected cells
or mice hydrodynamically injected with HBV replicative plasmids,
but they cannot faithfully recapitulate the in vivo infection process.
Even with these caveats in mind, the field is advancing toward an
understanding of the interaction between HBV and the human
innate immune system. Until recently, it was believed that the
virus was just a stealth pathogen that could not be detected by
PRRs (43–45). However, it is becoming clear that HBV just have a
number of very efficient strategies to block innate immunity, and
they were recently reviewed in Ref. (5, 46). Indirect data seem to
support the fact that PRR sensing of HBV is important for HVB
pathogenesis. For example, Guo et al. showed that transfection
in cells with the plasmids expressing adaptors for PRRs signal-
ing pathways (myeloid differentiation primary response gene 88,
or MyD88), TIR-domain-containing adaptor-inducing beta inter-
feron (TRIF), or the RIG-I/MDA5 adaptor, interferon promoter
stimulator 1 (IPS-1), reduced HBV DNA and RNA levels (47).
However, it is difficult to conclude that the data obtained in this
in vitro system correlates with the behavior of the virus in naturally
infected hosts.
CELLULAR MEMBRANE AND ENDOSOME SENSING
Using the HBV/WHV model, Zhang et al. described that addition
of TLR2 ligands activate NF-κB, PI3K/Akt, and different arms
of the MAPK signaling pathways to induce pro-inflammatory
cytokines, leading to the reduction of WHV replication and gene
expression in HepG2.2.15 cells and primary woodchuck hepato-
cytes (48). However, in a previous study using an HBV transgenic
mice model, a single intravenous injection of exogenous ligands
specific for TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9 showed
that all of the ligands except for TLR2 inhibited HBV replication
in the liver non-cytopathically in an alpha/beta IFN-dependent
manner (49). Differences in these results could easily be attributed
to the different model systems used, and warrant further inves-
tigation. In a more relevant study model, i.e., the chimpanzee,
Lanford et al. showed that the small molecule GS-9620, which
activates TLR7 signaling in immune cells, provided long-term sup-
pression of serum and liver HBV DNA (50). Based on these and
other results, TLR ligands are being developed as drugs for the
treatment of chronic viral infections, including HBV (51).
INTRACELLULAR SENSING
RIG-I and MDA5 are important PRRs responsible for recogni-
tion of viral RNAs produced during viral infection, and represent
targets for immunosuppression during HBV infection. Lu and
Liao demonstrated that in human Huh7 cells transfected and in
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the livers of mice hydrodynamically injected with HBV replicative
plasmids, the expression of MDA5, but not RIG-I, was increased,
and it was the critical protein for HBV detection (52). It is inter-
esting that mice heterozygous for MDA5 also had an increase in
HBV replication, indicating the existence of a possible threshold in
MDA5 expression level necessary for its function as a HBV sensor.
In another study, Zhao et al. proposed that RIG-I, and not MDA5,
is the protein involved in HBV sensing (53). Although it is not
clear as yet which specific sensor is involved, viral RNA sensing in
the cytoplasm is clearly occurring during HBV infection. Studies
using hepatocytes (54), 293 cells (55), or the cytoplasmic fraction
of HBx transgenic mouse livers (56) showed that hepatitis B virus
X (HBX) protein interacts with MAVS (also called IPS-1, a crit-
ical molecule in RNA signaling pathways) (57), and prevents the
induction of IFN genes. DNA sensing mechanisms are also likely
to be relevant, since in the cell line Huh7, Chen et al. showed
that DAI can inhibit HBV replication, where the inhibitory effect
was associated with activation of NF-κB, and was independent of
IRF-3 or cytokines (58).
In summary, it is clear that many more studies identifying new
mechanisms of HBV detection by the innate immune system are
likely to follow. The true challenge will be to reconcile those in vitro
identified pathways with the mechanisms of HBV control in more
relevant infectious models, i.e., the chimpanzee, and translate this
knowledge into human settings.
HERPESVIRUSES: EPSTEIN–BARR VIRUS AND KAPOSI’S
ASSOCIATED SARCOMA VIRUS
There is a significant body of data demonstrating that her-
pesviruses can be sensed by the innate immune system at the
cellular membrane, in the endosomes, and in the cytosol. Further-
more, recent studies showed that herpesviruses can also be sensed
in the nuclei. A recent comprehensive review on herpesviridae
was published by Paludan and Bowie (24). EBV and KSHV are
the two members of this virus family that have been identified as
having growth transforming potential, and therefore, we focus on
these here.
EPSTEIN–BARR VIRUS
Epstein–Barr virus was discovered approximately 50 years ago. It
is an enveloped virus with a dsDNA genome, for which there is
extensive knowledge about its biology (59). The innate immune
recognition of EBV was also reviewed in detail (60, 61).
CELLULAR MEMBRANE AND ENDOSOME SENSING
Epstein–Barr virus can be sensed by TLR2 in certain cells; how-
ever, the exact virion component being sensed is still unclear (62).
Ariza et al. proposed that deoxyuridine triphosphate nucleotido-
hydrolase (dUTPase), a non-structural protein encoded by EBV,
is sensed by TLR2 and initiates a MyD-88 dependent response
(63). This group further extended their results to demonstrate
that the protein was secreted in exosomes inducing NF-κB activa-
tion and cytokine secretion in primary DCs and peripheral blood
mononuclear cells (PBMCs) (64). However, these results should
be interpreted with caution given that the studies were done using
an in vitro experimental system. EBV produces non-coding RNAs
or “Epstein–Barr virus-encoded small RNA” (“EBER”). TLR3 is a
sensor of viral dsRNA. Very interestingly, it was discovered that a
substantial amount of EBER was released from EBV-infected cells
in exosomes that stimulated DCs to produce type-I IFN. Most
importantly, they found EBER in sera from patients with EBV-
related diseases, suggesting that EBER could be responsible for
immune activation by EBV, inducing type I IFN and proinflam-
matory cytokines (65). These results were further discussed by the
same group (66). TLR7 has not been proposed as a direct sensor
for EBV. However, Valente et al. reported that the aberrant activa-
tion of TLR7 in EBV-infected cells might induce the expression of
the EBV-protein LMP1 (67). As LMP1 is known to prime cells to
express IFN, and both TLR7 and IFNs are believe to be involved in
the development of systemic lupus erythematosus (SLE, or sim-
ply “lupus”), the association of EBV infection and autoimmunity
clearly warrants further investigation.
Interestingly, Severa et al. showed that EBV can activate
pDCs through TLR9 and TLR7, in combination with functional
autophagic machinery (68). However, these pDCs were not able
to mature and induced an inefficient T-cell response, suggesting a
new virus escape mechanism potentially related to EBV induced
diseases. Another important finding reported by van Gent et al.
showed that EBV encoded deubiquitinase, BPLF1, interferes with
NF-κB activation mediated by TLR signaling (69). TLR9 can initi-
ate a response by detecting EBV DNA in the endosomes. However,
Fathallah et al. showed that EBV infection of human primary B
cells results in the strong inhibition of TLR9 transcription by the
EBV oncoprotein latent membrane protein 1 (LMP1) (70). The
role of TLR9 in EBV infection has been exhaustively reviewed in
Ref. (7).
INTRACELLULAR SENSING
In the cytosol, EBV EBERs are recognized by RIG-I (62). More-
over, RIG-I has been proposed to indirectly sense EBV DNA by
recognizing the 5′-triphosphate transcribed by the host RNA poly-
merase III (71). However, there are conflicting results that need
to be resolved by further experimentation to clarify the role of
RNApol-III in EBV sensing mechanism (62). There are numer-
ous DNA sensors in the cytosol, and although some of them have
been shown to recognize other herpesviruses (62), the relevance
of cytosolic DNA sensors to EBV remains unclear.
KAPOSI’S ASSOCIATED SARCOMA VIRUS
This virus, formally classified as human herpesvirus 8 (HHV-8),
is associated with Kaposi’s sarcoma (KS), among other patholo-
gies (72). It is a big enveloped virus with a dsDNA genome (73).
Employing many proteins and micro-RNAs, KSHV modulates the
innate and adaptive immune system of the host at multiple levels.
A number of excellent reviews on these topics have been recently
published (8, 73–75).
CELLULAR MEMBRANE AND ENDOSOME SENSING
Only recently, researchers have started investigating the role of
TLR-mediated sensing of KSHV. Although a direct interaction of
KSHV with a TLR has not been reported, the virus downregu-
lates the expression of TLR4 soon after infection in endothelial
cells (76). West and Damania, however, showed that in mono-
cytes TLR3 expression is upregulated after KSHV infection (77).
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Gregory et al. showed that agonists specific for TLR7/8 reacti-
vated latent KSHV and induced viral lytic gene transcription and
replication (78). Moreover, the same was accomplished by sec-
ondary infection with vesicular stomatitis virus (VSV), which also
activates those same TLRs. More recently, pDCs were shown to
respond to KSHV in TLR9-dependent manner (79). Finally, it has
been shown that stimulation of the TLR3–TRIF axis increases the
expression of the KSHV protein RTA (replication and transcrip-
tion activator), only for RTA to degrade TRIF in order to block
the innate immune response (80, 81). Collectively, although these
results do not demonstrate a direct interaction between KSHV and
TLRs, they clearly indicate that there is a physiologically relevant
interplay between them.
INTRACELLULAR SENSING
The field of intracellular sensing of KSHV has recently seen a
number of very exciting discoveries. Gregory et al. reported that
KSHV Orf63 blocks NLRP1-dependent innate immune responses,
including caspase-1 activation and processing of interleukin-1 beta
(IL-1beta) and IL-18, and significantly reduces NLRP1-dependent
cell death (82). Moreover, the inhibition of Orf63 expression
resulted in increased expression of IL-1beta during the KSHV
infection that could have an effect on KSHV induced patholo-
gies. In a new development in the field of innate immune sensing,
Unterholzner et al. reported that IFI-16 acts as a nuclear sensor
for HSV-1 (23). Based on their findings, they proposed the exis-
tence of a new family of “AIM-2 like receptors” or ALRs. In the
same line of research, Kerur et al. found that the same protein is
responsible for KSHV sensing through an IFI-16/ASC inflamma-
some assembled in the nuclei (83). They reported that caspase-1
activation is IFI-16/ASC inflammasome dependent, and it leads
to IL-1b secretion. Moreover, the same group proposed that latent
KSHV genome is continuously sensed in the nuclei through IFI-16
sensing mechanism (84). Further studies will be needed to shed
light on the biological significance of these very exciting findings.
Finally, West et al. suggested a role for MAVS and RIG-I dependent
signaling mechanisms during KSHV infection (85). Therefore, all
of the families of cytosolic sensors have been implicated in the
recognition of KSHV. These results clearly indicate that KSHV has
a complex interaction with host innate immunity by activating sev-
eral PRRs. It is conceivable that activation of this network of innate
immune receptors is a necessary step in the virus pathogenesis to
establish lifelong persistence of the virus infection.
HUMAN PAPILLOMAVIRUSES
The HPV family encompasses a large number of stable dsDNA
viruses (86). Infections with high-risk HPVs are causally asso-
ciated with the development of anogenital cancers (87). It has
been proposed that HPVs evade the innate immune response of
the host cells by deregulating immunomodulatory factors such as
cytokines and chemokines, thereby creating a microenvironment
that favors malignancy (88). The combination of knowledge from
the fields of basic HPV virology and vaccinology was the driving
force for the successful development of clinically effective vaccines
against HPV (89). However, the developed vaccines are prophy-
lactic, not therapeutic, and cover only a subset of HVP types. It is
certainly clear that improving our understanding of the interaction
of HPV with the innate immune system will improve the prob-
ability of success in developing better treatments. Similar to all
other viruses described in this review, experimental systems that
would be informative about HPV pathogenesis in humans are very
limited. The vast majority of studies were performed using virus
like particles (VLPs). This approach, and the differences between
laboratories in their techniques for virus particles preparation, is
partially responsible for the incomplete understanding of HPV
biology. For example, the exact mechanism of virus entry into the
cell remains incompletely defined (90). Along the same lines, the
full spectrum of PRRs relevant to HPV recognition by the cell is
yet to be determined.
CELLULAR MEMBRANE AND ENDOSOME SENSING
The current understanding of the interaction between HPV and
PRRs is mostly based on studies aimed to potentiate immunolog-
ical responses to HPV vaccines by modulating innate immunity.
Therefore, research in the field has focused primarily on the role
of TLRs. To date there are no publications on the involvement of
cytosolic or nuclear sensors in HPV recognition. There is cur-
rently no evidence that any cellular PRRs interact with HPV
directly [reviewed in Ref. (88)]. A comprehensive review on the
role of TLRs in HPV infection has been recently published by
Zhou et al. (91). Although TLR4 was suggested to bind HPV L1
directly, these studies were performed using VLPs, and although
TLR9 may recognize HPV DNA in the endosomes, it is not clear
whether the HPV DNA is exposed in the endosome during nat-
ural viral infections (91). More recently, it was described that
an HPV16 transcriptional repressor complex associates with the
TLR9 promoter, suggesting that blocking this TLR-mediated sens-
ing pathway may be of significance for the virus pathogenesis
(92). Collectively, these data indicate that although direct inter-
action between HPV and PRRs is yet to be shown, the virus
does interfere with innate pathogen recognition machinery. In
this regard, several recent publications describing how HPV may
control cellular responses initiated by PRRs pathways should be
mentioned. IL-1beta is a critical cytokine that mediates inflam-
mation and is important for both innate and adaptive immunity.
Using immortalized keratinocytes, it was shown that the high-
risk HPV16 E6 oncoprotein can abrogate IL-1beta processing and
secretion independently of the NALP3 inflammasome (93). The
authors further demonstrated that pro-IL-1beta is degraded by a
novel proteasome-dependent mechanism via the ubiquitin ligase
E6-AP and p53. Moreover, in a panel of HPV-positive tissue sam-
ples, the authors found correlation between reduced amounts of
IL-1beta and the stage of cellular progression toward cervical can-
cer (93). HPV was also shown to interfere with innate immune
signaling pathways through virus-dependent upregulation of an
intrinsic ubiquitin ligase, ubiquitin carboxyl-terminal hydrolase
L1 (UCHL1). Upregulation of UCHL1 inhibited TRAF-3 depen-
dent phosphorylation of interferon regulatory factor-3 (IRF-3),
and the activation of NF-κB (94). However, the role of this ubiq-
uitin ligase in vivo remains unclear as these studies were performed
in HPV infected keratinocytes. Using an in vitro approach, Sun-
thamala et al. found that HPV E2 protein interferes with innate
immune signaling pathways by downregulating STING and IFN-κ
(9). Importantly, they also demonstrated in clinical specimens that
www.frontiersin.org July 2014 | Volume 5 | Article 353 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Di Paolo Oncogenic viruses recognition by PRRs
STING and IFN-κ are downregulated in HPV low grade lesions
when compared to normal tissues. Conceptually and mechanisti-
cally interesting findings were made by Kumar et al., who showed
that Langerhans cells from cervical tumors lack TLR9 expression
and are functionally anergic to TLR7, TLR8, and TLR9 ligands
(95). These data suggest that apart from directly interacting with
cellular PRRs, HPV may interfere with innate signaling pathways
in neighboring cells in an indirect paracrine manner leading to
PRRs signaling inhibition.
HUMAN T-CELL LYMPHOTROPIC VIRUS
Human T-cell lymphotropic virus-1 belongs to the retroviri-
dae family and is an enveloped, round shaped particle with a
single-stranded RNA genome (96). The diseases that induce are
diverse and this diversity in clinical manifestations in response
to HTLV-1 is likely associated with genetic heterogeneity of the
host. The pathologies induced by this virus include the aggres-
sive, fatal T-cell malignancy adult T-cell leukemia (ATL) and a
chronic, progressive neurologic disorder called HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), among oth-
ers. Unfortunately, the molecular mechanisms underlying the
diversity in host responses to HTLV-1 remain unclear (96). The
studies of host defense against HTLV-1 have largely focused on
understanding the very strong CTL response against the virus. It
is puzzling how the virus can establish a persistent infection in
the face of such a response. One of the potential mechanisms to
escape from the CTL response is the capacity of the virus to down-
regulate the expression of all but one viral protein (HBZ), thus
directly reducing the immunogenicity of the infected cells (97).
This capacity of the virus also makes its detection by the innate
immune system very challenging. Several reviews have recently
summarized the advances in the field of HTLV-1 interactions with
the innate immune system (10, 97–99).
The fact that there is not an adequate animal model to study
the virus interaction with innate immunity makes advancing in
the field very challenging. Rabbits and monkeys models can be
used; however, the available immunological tools are scarce. For
HTLV-1, mice represent a very poor animal model. Finally, in
contrast to the availability of human cervix samples for studies
of HPV pathogenesis, access to central nervous system tissue of
HTLV-1 infected individuals is not available (100, 101). Therefore,
it is not surprising that as of yet there is no evidence of direct
recognition of HTLV-1 by PRRs. Furthermore, the role of innate
immunity in HTLV-1-associated diseases is not clear (99). Only
recently, the induction of an innate immune response to HTLV-
1 (102) was reported for the first time. The authors found that
cell-free HTLV-1 stimulates pDCs to produce massive amounts
of type-I IFN. The proposed mechanism of type-1 IFN induc-
tion was the degradation of the viral particles in the endosomal
compartments, and consequent exposure of the ssRNA to TLR7.
This model was supported by the indirect observations that an
endosomal acidification inhibitor and a TLR7 specific blocker
drastically inhibited pDC response to HTLV-1 measured by type-
1 IFN production. Progress in understanding the innate immune
responses to HTLV-1 may come from the use of humanized
mouse models (100). For example, reconstitution of mice with
WT or TLR7 deficient human cells may reveal the contribution
of the TLR7 innate immune signaling pathway to recognition of
HTLV-1.
MERKEL CELL POLYOMAVIRUS
Merkel cell carcinoma (MCC) is a highly aggressive non-
melanoma skin cancer arising from epidermal mechanoreceptor
Merkel cells. In 2008, a novel human polyomavirus, MCPyV,
was identified and is now implicated in MCC pathogenesis.
Polyomaviruses are small, non-enveloped dsDNA viruses [for a
detailed review on polyomaviruses and MCPyV in particular see
Ref. (11, 46, 103, 104)]. Although little is known about this newly
identified virus, it is plausible that, as with other oncogenic viruses,
MCPyV has an array of mechanisms to block the innate immune
responses. There is limited information on the innate immune
recognition of this virus, as the field is in its infancy. It was reported
that MCPyV large T antigen (LT) expression downregulates TLR9
expression in epithelial and MCC-derived cells (105), but nothing
is known regarding the direct recognition of the virus by PRRs.
More data are clearly needed on the interaction of this virus with
the innate immune system.
CONCLUSION
Over evolutionary times, the battle between the oncogenic viruses
and their hosts has arrived at a balance that ensures the survival
of both organisms. However, with the current advances in vacci-
nology and drug development, it is plausible to imagine that we
are potentially getting closer to limiting the impact these seven
viruses have on the population of the world. Although a com-
plete understanding of all of the complexity of interactions with
the native host for all of the oncogenic viruses discussed in this
review is still lacking, it is clear that the innate immune system
is able to recognize their presence through a network of sensors.
Undoubtedly, the understanding of virus interactions with the
innate immune system will aid in the development of effective
treatments against these pathogens. More research is clearly war-
ranted to devise effective approaches to harness the tools of the
innate immune system for elimination of these viral pathogens
without negatively affecting their hosts.
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